The application of PP2A-activating drugs (PADs, such as FTY720) suppressed the JAK2/β-catenin pathway via PP2A with consequences to quiescent LSCs survival, suggesting the application of PADs to improve the prognosis in TKI-refractory CML [104]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.